A microbubble composition, comprising: a plurality of microbubbles, a microbubble comprising a noble gas and/or perfluorocarbon encapsulated within a shell that comprises one or more of a lipid, a protein, or a polymer, and a microbubble optionally defining a cross-sectional dimension in the range of from about 0.5 to about 20 micrometers. A method, comprising forming a composition according to the present disclosure. A method, comprising administering a microbubble composition according to the present disclosure to a subject, the composition optionally comprising echogenic phospholipid microbubbles. A method, comprising: (a) identifying, with the application of energy, the location of a microbubble composition according to the present disclosure, the energy optionally being ultrasound, (b) controllably effecting rupture of microbubbles of a microbubble composition of the present disclosure, the rupture optionally being effected by application of ultrasound, or both (a) and (b).

The present invention relates to a microcapsule composition in which polydopamine-coated calcium carbonate microspheres are encapsulated by forming an alginate gel on the surface of a spheroid conjugated thereto, and a method of preparing the same, and it is confirmed that according to the method of preparing the microcapsule, the drug or physiologically active material was individually microencapsulated by gradually forming an alginate gel on the surface of the spheroid containing the drug or physiologically active material, a drug or a bioactive material is placed in the center of a capsule in a very simple way, and a capsule of a very small size can be manufactured in a short time compared to the conventional encapsulation method by adjusting the size of the capsule.

The invention generally relates to sonodynamic therapy using microbubble-sonosensitiser complexes and, more specifically, to such therapy for the treatment of deeply-sited tumours and associated metastatic disease. In particular, the invention relates to a combination therapy in which sonodynamic treatment of deeply-sited tumours with microbubble-sonosensitiser complexes is combined with treatment using immune checkpoint inhibitors. It further relates to methods of sonodynamic therapy in which a sonodynamic-induced abscopal response modulates a systemic regression of metastatic disease. In such methods the abscopal response may be further enhanced by co-administration of an immune checkpoint inhibitor. The invention is particularly suitable for the treatment of pancreatic cancer (e.g. pancreatic ductal adenocarcinoma) and associated metastasis.

The present invention generally relates to particles, including nanocapsules or other nanoentities, comprising a polymer such as polysialic acid. The particles are able to access the interior of the cells, and/or to procure the intracellular release of the associated drugs. In 5 one aspect, the present invention is directed to nanocapsules or other entities having an exterior or surface comprising a polymer such as polysialic acid. In some cases, targeting moieties such as Lyp-1 or tLyp-1 peptide are bonded to the polymer, e.g., using aminoalkyl (C.sub.1-C.sub.4) succinimide or other linkers. These may be created, for example, by reacting a carboxylate moiety on a polymer with an aminoalkyl maleimide (C.sub.1-C.sub.4) or an aminoalkyl 10 (C.sub.1-C.sub.4) methacrylamide, and reacting the resulting aminoalkyl (C.sub.1-C.sub.4) maleimide or the aminoalkyl (C.sub.1-C.sub.4) methacrylamide to a cysteine or other sulfur group. Targeting moieties are bonded to the polymer, for example, by reacting a carboxylate moiety on a polymer with a N-hydroxysuccinimide or a carbodiimide, and reacting the intermediate formed with a lysine or arginine group on a targeting peptide to produce polymer-amide-peptide. Other 15 aspects of the invention are generally directed to methods of making or using such compositions, kits including such compositions, or the like.

The present invention relates to compositions and methods to treat and/or prevent biofilms and biofilm related diseases. The invention comprises a nanoparticle carrier (NPC) and at least one therapeutic agent therein. The NPC binds within biofilm and to surfaces at risk for biofilm formation and accumulation while providing local, sustained, enhanced and controlled delivery of the therapeutic agent, when triggered for release. In one embodiment, the NPC comprises pH-responsive elements that allows for specific delivery of the therapeutic agent when the local environment dictates that the agent should be delivered precisely when it is most needed.

The invention relates to inhibitors of the PKC signaling pathway for use in the treatment of septic cholestasis, wherein the inhibitors are targeted into the liver by a selective nanostructured delivery system, wherein the selective nanostructured delivery system comprises at least one carbohydrate targeting moiety and at least one polymer and/or at least one lipid and/or at least one virus-like particle.

Nanoparticle compositions for delivery of nucleic acids to subjects including modified dendrimers comprising cores, one or more of homogeneous or heterogeneous intermediate and terminal layers, and therapeutic or immunogenic nucleic acid agents enclosed within nanop article compositions are described. Methods for treating or preventing diseases or conditions in a subject by administering the nanoparticle compositions that provide immune responses and synergistic therapeutic or preventive effects are provided.

The present disclosure is directed to polymer nanocapsules including a ribonucleoprotein complex, and methods of their delivery. In some embodiments, the polymer nanocapsule comprises a polymer shell and a ribonucleoprotein complex, wherein the polymer shell comprises at least one positively charged monomer, at least one neutral monomer, and a crosslinker. Also disclosed are conjugates of polymer nanocapsules coupled to one or more targeting moieties and/or one or more stabilizing moieties.

Methods of preparing red blood cell mimetics and functionalized red blood cell mimetics, and methods of making and using those mimetics, are provided.

The present disclosure relates to a nanoparticle complex that is taken into cells to be used for the treatment of diseases, and a method of manufacturing the same using a top-down process. In the top-down process, surfaces of nanoparticles are modified with a lipid-based material having high stability and excellent biocompatibility, thereby improving endocytosis efficiency. A lipid structure having a tube shape is bonded to a portion of the surface of the nanoparticle, so that the nanoparticle complex undergoes endocytosis, directly penetrates a cell membrane, and is effectively taken into spheroid-type tumor cells. The lipid structure is not directly attached to the nanoparticles, lipid-based lipidomes (such as bubbles and liposomes) are bonded to the nanoparticles, and mechanical force is applied thereto to thus crush the lipidomes, so that the lipid structure is formed on the surface of the nanoparticle.